These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 26851656)
1. EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents. Arendrup MC; Meletiadis J; Mouton JW; Guinea J; Cuenca-Estrella M; Lagrou K; Howard SJ; Clin Microbiol Infect; 2016 Jun; 22(6):571.e1-4. PubMed ID: 26851656 [TBL] [Abstract][Full Text] [Related]
2. EUCAST technical note on Aspergillus and amphotericin B, itraconazole, and posaconazole. Arendrup MC; Cuenca-Estrella M; Lass-Flörl C; Hope WW; Clin Microbiol Infect; 2012 Jul; 18(7):E248-50. PubMed ID: 22540149 [TBL] [Abstract][Full Text] [Related]
3. How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST). Arendrup MC; Friberg N; Mares M; Kahlmeter G; Meletiadis J; Guinea J; Clin Microbiol Infect; 2020 Nov; 26(11):1464-1472. PubMed ID: 32562861 [TBL] [Abstract][Full Text] [Related]
4. Multicentre determination of quality control strains and quality control ranges for antifungal susceptibility testing of yeasts and filamentous fungi using the methods of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Cuenca-Estrella M; Arendrup MC; Chryssanthou E; Dannaoui E; Lass-Florl C; Sandven P; Velegraki A; Rodriguez-Tudela JL; Clin Microbiol Infect; 2007 Oct; 13(10):1018-22. PubMed ID: 17697001 [TBL] [Abstract][Full Text] [Related]
13. Antifungal susceptibility of bloodstream yeasts isolated at a public children's hospital in Brazil: comparison of the Etest and the AFST-EUCAST microdilution method. Matsumoto FE; Dias AL; Melhem MS; Szeszs MW; Auler ME; Ruiz LS; Gonçalves da Silva E; Gandra RF; Paula CR Can J Microbiol; 2007 Dec; 53(12):1300-6. PubMed ID: 18059562 [TBL] [Abstract][Full Text] [Related]
15. Candida and candidaemia. Susceptibility and epidemiology. Arendrup MC Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246 [TBL] [Abstract][Full Text] [Related]
16. Revision of EUCAST breakpoints: consequences for susceptibility of contemporary Danish mould isolates to isavuconazole and comparators. Jørgensen KM; Guinea J; Meletiadis J; Hare RK; Arendrup MC J Antimicrob Chemother; 2020 Sep; 75(9):2573-2581. PubMed ID: 32556315 [TBL] [Abstract][Full Text] [Related]
17. Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp. Arendrup MC; Cuenca-Estrella M; Lass-Flörl C; Hope WW Drug Resist Updat; 2013 Dec; 16(6):81-95. PubMed ID: 24618110 [TBL] [Abstract][Full Text] [Related]
18. In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis. Bueno JG; Martinez C; Zapata B; Sanclemente G; Gallego M; Mesa AC Clin Exp Dermatol; 2010 Aug; 35(6):658-63. PubMed ID: 19874354 [TBL] [Abstract][Full Text] [Related]
19. The role of epidemiological cutoff values (ECVs/ECOFFs) in antifungal susceptibility testing and interpretation for uncommon yeasts and moulds. Espinel-Ingroff A; Turnidge J Rev Iberoam Micol; 2016; 33(2):63-75. PubMed ID: 27296911 [TBL] [Abstract][Full Text] [Related]
20. In vitro susceptibility-testing in Aspergillus species. Lass-Flörl C; Perkhofer S Mycoses; 2008 Sep; 51(5):437-46. PubMed ID: 18422914 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]